Clinical Trial

Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

Study acronym: BEAVER
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-centre, open-label Phase II study of the investigational drugs binimetinib and encorafenib that will be taken my mouth (orally) daily in adult patient with advanced and/or metastatic solid tumors for which no other standard therapy is available. The main purpose is to evaluate the objective response rate (ORR) of the study drugs in the growth of the cancer in patients with class 2 and 3 BRAF mutations.
Trial Details
NCT Number NCT03839342
Lead Sponsor University Health Network, Toronto
Conditions Solid Tumor
Enrollment 26 participants
Start Date 2019-06-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-08